BR112017026278A2 - 1,5-di-hidro-4h-pirazolo[3,4-d]pirimidin-4-onas e 1,5-di-hidro-4h-pirazolo[4,3-c]piridin-4-onas como inibidores de pde1 - Google Patents

1,5-di-hidro-4h-pirazolo[3,4-d]pirimidin-4-onas e 1,5-di-hidro-4h-pirazolo[4,3-c]piridin-4-onas como inibidores de pde1

Info

Publication number
BR112017026278A2
BR112017026278A2 BR112017026278-9A BR112017026278A BR112017026278A2 BR 112017026278 A2 BR112017026278 A2 BR 112017026278A2 BR 112017026278 A BR112017026278 A BR 112017026278A BR 112017026278 A2 BR112017026278 A2 BR 112017026278A2
Authority
BR
Brazil
Prior art keywords
pyrazolo
dihydro
ones
pde1
pyrimidin
Prior art date
Application number
BR112017026278-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Juhl Karsten
Jessing Mikkel
Langgård Morten
Jorge Vieira Vital Paulo
Marigo Mauro
Kehler Jan
Kyhn Rasmussen Lars
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of BR112017026278A2 publication Critical patent/BR112017026278A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112017026278-9A 2016-04-12 2017-04-07 1,5-di-hidro-4h-pirazolo[3,4-d]pirimidin-4-onas e 1,5-di-hidro-4h-pirazolo[4,3-c]piridin-4-onas como inibidores de pde1 BR112017026278A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600221 2016-04-12
DKPA201600221 2016-04-12
PCT/EP2017/058332 WO2017178350A1 (en) 2016-04-12 2017-04-07 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors

Publications (1)

Publication Number Publication Date
BR112017026278A2 true BR112017026278A2 (pt) 2018-09-11

Family

ID=58489694

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026278-9A BR112017026278A2 (pt) 2016-04-12 2017-04-07 1,5-di-hidro-4h-pirazolo[3,4-d]pirimidin-4-onas e 1,5-di-hidro-4h-pirazolo[4,3-c]piridin-4-onas como inibidores de pde1

Country Status (43)

Country Link
US (3) US20170291901A1 (cg-RX-API-DMAC7.html)
EP (1) EP3442975B1 (cg-RX-API-DMAC7.html)
JP (1) JP7093306B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180133413A (cg-RX-API-DMAC7.html)
CN (1) CN109071549B (cg-RX-API-DMAC7.html)
AR (1) AR108109A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017250431B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017026278A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020053A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018002881A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018010323A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180470A (cg-RX-API-DMAC7.html)
CY (1) CY1123269T1 (cg-RX-API-DMAC7.html)
DK (1) DK3442975T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2018000201A (cg-RX-API-DMAC7.html)
EA (1) EA035197B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP18074641A (cg-RX-API-DMAC7.html)
ES (1) ES2814289T3 (cg-RX-API-DMAC7.html)
GE (2) GEAP201914901A (cg-RX-API-DMAC7.html)
HR (1) HRP20201331T1 (cg-RX-API-DMAC7.html)
HU (1) HUE050320T2 (cg-RX-API-DMAC7.html)
IL (1) IL262257B (cg-RX-API-DMAC7.html)
LT (1) LT3442975T (cg-RX-API-DMAC7.html)
MA (1) MA44656B1 (cg-RX-API-DMAC7.html)
ME (1) ME03820B (cg-RX-API-DMAC7.html)
MX (1) MX374251B (cg-RX-API-DMAC7.html)
MY (1) MY194722A (cg-RX-API-DMAC7.html)
NI (1) NI201800092A (cg-RX-API-DMAC7.html)
PE (1) PE20181853A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018502168A1 (cg-RX-API-DMAC7.html)
PL (1) PL3442975T3 (cg-RX-API-DMAC7.html)
PT (1) PT3442975T (cg-RX-API-DMAC7.html)
RS (1) RS60714B1 (cg-RX-API-DMAC7.html)
RU (1) RU2018133391A (cg-RX-API-DMAC7.html)
SG (1) SG11201808221QA (cg-RX-API-DMAC7.html)
SI (1) SI3442975T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000446T1 (cg-RX-API-DMAC7.html)
SV (1) SV2018005753A (cg-RX-API-DMAC7.html)
TN (1) TN2018000321A1 (cg-RX-API-DMAC7.html)
TW (1) TWI729109B (cg-RX-API-DMAC7.html)
UA (1) UA121925C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017178350A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201806407B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
EP3562828B1 (en) 2016-12-28 2026-03-18 Dart Neuroscience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
US20220184240A1 (en) 2019-04-12 2022-06-16 Intra-Cellular Therapies, Inc. Organic compounds
CN115304607B (zh) * 2022-07-06 2023-06-27 华南农业大学 吡唑并嘧啶衍生物的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) * 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) * 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
WO2004099211A1 (de) 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
PT2152712E (pt) * 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
EP2227472A1 (en) 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
EP2575817A4 (en) * 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
EP3181566A1 (en) 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
MX381326B (es) 2011-10-10 2025-03-12 H Lundbeck As Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
TW201609713A (zh) * 2013-12-19 2016-03-16 H 朗德貝克公司 作爲pde1抑制劑之喹唑啉-thf-胺
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JP2018508555A (ja) 2015-03-16 2018-03-29 大日本住友製薬株式会社 二環性イミダゾロ誘導体
TW201643167A (zh) 2015-04-22 2016-12-16 H 朗德貝克公司 作爲pde1抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP2018076285A (ja) 2016-09-14 2018-05-17 大日本住友製薬株式会社 二環性イミダゾロ誘導体を含む医薬
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов

Also Published As

Publication number Publication date
ES2814289T3 (es) 2021-03-26
US10538525B2 (en) 2020-01-21
GEP20207057B (en) 2020-01-27
JP2019517996A (ja) 2019-06-27
NI201800092A (es) 2019-03-14
IL262257B (en) 2020-11-30
CY1123269T1 (el) 2021-12-31
KR20180133413A (ko) 2018-12-14
TW201738242A (zh) 2017-11-01
RS60714B1 (sr) 2020-09-30
PT3442975T (pt) 2020-09-03
IL262257A (en) 2018-11-29
HRP20201331T1 (hr) 2020-11-27
DOP2018000201A (es) 2018-11-15
SMT202000446T1 (it) 2020-09-10
HUE050320T2 (hu) 2020-11-30
DK3442975T3 (da) 2020-08-24
MX2018012496A (es) 2019-02-21
LT3442975T (lt) 2020-09-25
CN109071549A (zh) 2018-12-21
ECSP18074641A (es) 2018-10-31
AU2017250431B2 (en) 2020-07-16
AU2017250431A1 (en) 2018-10-11
CN109071549B (zh) 2021-11-30
SV2018005753A (es) 2018-11-27
US20190194204A1 (en) 2019-06-27
CR20180470A (es) 2018-12-21
AR108109A1 (es) 2018-07-18
RU2018133391A (ru) 2020-05-12
EA035197B1 (ru) 2020-05-14
PL3442975T3 (pl) 2020-11-16
EP3442975B1 (en) 2020-07-29
EP3442975A1 (en) 2019-02-20
SI3442975T1 (sl) 2020-10-30
JP7093306B2 (ja) 2022-06-29
CO2018010323A2 (es) 2018-12-14
PE20181853A1 (es) 2018-12-03
MX374251B (es) 2025-03-05
CA3020053A1 (en) 2017-10-19
ME03820B (me) 2021-04-20
EA201891897A1 (ru) 2019-03-29
PH12018502168A1 (en) 2019-08-19
MA44656B1 (fr) 2020-10-28
SG11201808221QA (en) 2018-10-30
US11104680B2 (en) 2021-08-31
TWI729109B (zh) 2021-06-01
ZA201806407B (en) 2019-12-18
UA121925C2 (uk) 2020-08-10
US20200102316A1 (en) 2020-04-02
RU2018133391A3 (cg-RX-API-DMAC7.html) 2020-06-23
WO2017178350A1 (en) 2017-10-19
MY194722A (en) 2022-12-15
TN2018000321A1 (en) 2020-01-16
CL2018002881A1 (es) 2018-12-14
US20170291901A1 (en) 2017-10-12
GEAP201914901A (en) 2019-09-25
MA44656A (fr) 2019-02-20

Similar Documents

Publication Publication Date Title
NI201800092A (es) 1,5-dihidro-4h-pirazolo [3, 4-d] pirimidin-4-onas y 1,5-dihidro-4h-pirazolo [4, 3-c] piridin-4-onas como inhibidores de pde1
CO2018013803A2 (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1
BR112016024626A2 (pt) 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas como inibidores de proteínas bet
BR112018009511A2 (pt) derivados de pirazolo pirimidina
CO2019005538A2 (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
GT201700223A (es) Imidazopirazinonas como inhibidores de pde 1
CR20160282A (es) Quinazolin-thf-aminas como inhibidores de pde1
CL2020001550A1 (es) Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas.
MX2016012955A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1.
BR112017011335A2 (pt) compostos de 4h-pirido[1,2-a]pirimidin-4-ona
EA201892549A1 (ru) ПРИМЕНЕНИЕ 1H-ПИРАЗОЛО[4,3-b]ПИРИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements